Can a daily supplement boost your Cells' energy? new study seeks answers

NCT ID NCT07428889

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot trial is testing whether a proprietary nutritional supplement can increase levels of NAD+, a molecule important for cellular energy and aging, in healthy adults aged 45 to 65. Participants will take either the supplement or a placebo daily for 60 days. The study aims to measure changes in NAD+ and related markers, as well as subjective feelings of cognitive function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

proprietary nutritional supplement containing nicotinamide metabolites and plant extracts

What this could lead to

If it works, this could point toward a supplement that supports cellular energy and healthy aging in adults.

What could go wrong

This is a very small, early pilot study in healthy people, so results may not apply to the general population or lead to any proven health benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Biofortis Clinical Research

    RECRUITING

    Addison, Illinois, 60101, United States

    Contact

    Contact Email: •••••@•••••